Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10

Rama R Varma1, Suzanne M Hector, Kimberly Clark

  • 1Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

Oncology Reports
|September 6, 2005
PubMed

Insights

This study identifies key genes, including Collagen VI (COL6A3), overexpressed in platinum-drug resistant ovarian cancer cells. Understanding these gene expression changes offers new insights into overcoming cancer treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Platinum-based chemotherapy is a cornerstone in ovarian cancer treatment.
  • Tumor cell resistance to platinum drugs significantly limits treatment efficacy.
  • Understanding the molecular mechanisms of drug resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To identify differentially expressed genes in an oxaliplatin-resistant human ovarian carcinoma cell line compared to its sensitive parental line.
  • To elucidate molecular pathways contributing to platinum drug resistance in ovarian cancer.
  • To validate the expression levels of selected genes using quantitative real-time RT-PCR.

Main Methods:

  • Gene expression profiling using Affymetrix HG-U95Av2 oligonucleotide arrays.
  • Statistical analysis of gene expression data using dChip, RMA, and SAM methods.
  • Validation of mRNA levels for key genes using real-time quantitative RT-PCR.

Main Results:

  • Identified 43 overexpressed and 39 underexpressed genes in the drug-resistant cell line.
  • Collagen VI (COL6A3) showed a 62-fold overexpression, being the most significantly upregulated gene.
  • Overexpressed genes were enriched in extracellular matrix and signal transduction categories, including matrix metalloproteinases (MMP3, MMP12).
  • Underexpressed genes included those involved in cell cycle and growth regulation, such as SOCS2, NDN, GPC3, and GPC4.

Conclusions:

  • The study identified specific genes and pathways associated with platinum drug resistance in ovarian cancer.
  • Upregulation of extracellular matrix genes like COL6A3 and MMPs, and downregulation of cell cycle regulators, are implicated in resistance.
  • These findings provide a foundation for understanding platinum resistance mechanisms and developing targeted therapies.

Related Concept Videos